Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs” or the “Company”), a
provider of quality assurance software under the PrintRite3D®
brand, today announced financial results for the fiscal year ended
December 31, 2018.
Highlights for 2018 and 2019 Developments
- Demonstrated proof of concept for closed loop quality control
during metal additive manufacturing. Using Sigma’s PrintRite3D®
technology, the system operates by monitoring the process output
and extracting process metrics. The process metrics are then
compared to baseline metrics. The system then determines what
process input parameter values need to be changed and implements
those remedial changes in real time.
- Launched PrintRite3D® 4.0 Product Suite with its
patent-applied-for TED and TEP features enabling rapid AM machine
optimization (TED) and in process quality assurance including
signatures of precursors of developing quality anomalies (TEP).
- Concurrent with the PrintRite3D® 4.0 release, the Company
introduced its Rapid Test and Evaluation Program enabling
qualifying customers to “try before they buy.”
- Entered into a Cooperative Research and Development Agreement
(CRADA) with the National Institute of Standards and Technology
(NIST) to help develop Additive Metal Manufacturing Standards in
the U.S.
- Awarded contract for its PrintRite3D® hardware, software and
engineering services by a federally funded organization involved in
the space industry.
- Awarded a Rapid Test and Evaluation Program contract with a
leading global materials and service provider in additive
manufacturing (AM).
- Awarded Rapid Test and Evaluation Program contract win in the
Oil and Gas Industry with a leading provider of integrated oilfield
products, services and digital solutions.
- Awarded three U.S. Patents, US 9,999,924, US 10,207,489 and US
10,226,817, that provide protections for methods of assuring part
quality using real time data from multiple sensor types.
- Closed offerings for total gross proceeds of $5,351,220;
$3,390,100 in 2018 and $1,961,120 in 2019.
- Darren Beckett and Dr. Martin Piltch assumed responsibilities
of retiring CTO and Founder, Mark Cola.
- Hired a Germany-based Business Development Manager and a London
based Applications Engineer to facilitate our continued expansion
into the European market.
- Hired a U.S.-based Business Development Manager, North and
South America.
- Joined Manufacturing Technology Centre to advance
industrialization of Additive Manufacturing with in-process quality
control.
- Sigma Labs and Fraunhofer IAPT announced a collaborative
research and development agreement to test and validate the use of
the PrintRite3D’s In-Process-Quality-Assurance suite to identify
and quantify machine and process inconsistencies as well as to
define in-process defect thermal signatures in the part formation
process and correlate them to CT scan results. Also named a member
of the Additive Alliance of Fraunhofer IAPT, a leading network for
Additive Manufacturing (AM). As the first US company to be granted
a membership in the Alliance, Sigma Labs becomes part of the global
research consortium to advance the development and implementation
of AM.
“2018 was a momentous and, we believe, decisive year for our
company. We completed a 17-month transition from an R&D company
fielding an R&D tool into a Technology Commercialization
company that introduced a commercial-industrial version of our
PrintRite3D in November 2018. Sigma then commenced rolling out this
technology through a Rapid Test and Evaluation Program directed at
companies that manufacture or buy metal 3D manufactured parts and
demand quality assurance solutions to improve yields and product
risks that are below their companies’ high standards,” said John
Rice, CEO of Sigma Labs. “The release to market of our TED and TEP
tools was a seminal moment for us as it means that now we can give
our customers the ability to identify inherent ‘built-in’
inconsistencies in 3D metal manufacturing equipment performance,
allowing them to immediately address these inconsistencies, and we
can discern the signatures of precursors of quality anomalies in
real time before most of these first emerging problems spoil part
quality. In 2018, we announced our successful proof of concept of
closed loop control. Our Ted and TEP tools are essential for
discerning and characterizing the information required by a closed
loop control system. We are pleased with our progress and our
pathway here.”
“In 2018, we also entered into and expanded our customer
footprint in new industry verticals, including the Oil and Gas
industry, as we implemented our increasingly successful Rapid Test
and Evaluation Program approach to market growth. We also were
awarded a contract for hardware, software and engineering services
by a federally funded organization involved in the space industry.
In order to expand our international sales opportunities, we hired
a Business Development Manager who headquarters in Munich, Germany,
an Applications Engineer who headquarters in Kingston upon Hull,
England and a Business Development Manager for the Americas. While
U.S. manufacturing employment has declined over the past 25 years,
the future outlook for technologies like 3D metal manufacturing
appears to be very bright. Taken alone, the U.S. manufacturing
sector would be the ninth-largest economy in the world, according
to the National Association of Manufacturers, in a new report
issued by IndustryWeek Custom Research and Kronos Incorporated. To
achieve their growth targets, manufacturers are investing in areas
that will improve productivity and speed responsiveness and Sigma
Labs now has a suite of products and services that can meet
important unfilled niches of these needs,” Mr. Rice concluded.
2018 Full Year Financial
Results
During the fiscal year ended December 31, 2018,
we recognized revenue of $388,574 as compared to $641,049
recognized in 2017, a $252,475 reduction resulting from the shift
from an emphasis on government and private industry funded research
and development sales to our Rapid Test and Evaluation Program
(“RTEP”).
Cost of sales for 2018 were $270,107 as compared
to $272,372 in 2017, a decrease of $2,265. This results from
a combination of higher optics and software systems costs of our
PrintRite3D® 4.0 Product Suite and the additional travel costs
associated with the onsite collaboration required with
RTEP.
Sigma’s operating expenses for that twelve months ended December
31, 2018, were $5,687,271 as compared to $4,267,654 for the twelve
months of fiscal 2017, a $1,419,617 increase. This increase
resulted primarily from a combination of the requisite increase in
salary and related costs of a 33% increase in employee count, the
accrual of severance costs under executive employment agreement,
increased internal R&D costs, higher travel cost for both
business development outreach and onsite collaboration activities
of RTEP and a more robust stock-based compensation program for both
directors and employees in 2018.
The combination of lower sales revenue, higher
cost of product and increased operations costs, discussed above,
resulted in an operating loss of $5,568,804 in 2018 compared to a
loss of $4,051,990 in 2017.
In 2018, our net other income and expense was a net expense of
$5,359 compared to net expense of $525,526 in 2017. The 2017
expense was largely due to the non-cash adjustments required for
the revaluation of derivatives and amortization of debt discounts
related to debt and equity financing activities in that year.
As of December 31, 2018, we had $1,279,782 in
cash and had a working capital surplus of $1,747,836, as compared
with $1,515,674 in cash and a working capital surplus of $2,656,695
as of December 31, 2017.
Investor Conference Call
Management will host a conference call today,
April 1, 2019 at 9:00 am eastern time to review financial results
and corporate highlights. Following management’s formal remarks,
there will be a question and answer session.
To listen to the call by phone, interested
parties within the U.S. should call 1-844-802-2441
and International callers should call 1-412-317-5134. All
callers should ask for the Sigma Labs conference call. The
conference call will also be available through a live webcast at
www.sigmalabsinc.com. Details for the webcast may be found on the
Company’s IR events page at:
http://client.irwebkit.com/sigmalabsinc/events.
A replay of the call will be available
approximately one hour after the end of the call through May 1,
2019. The replay can be accessed via Sigma Labs' website or by
dialing 877-344-7529 (domestic) or 412-317-0088 (international) or
Canada Toll Free at 855-669-9658. The replay conference ID number
is 10129976. The webcast replay will be available through July 1,
2019.
About Sigma Labs
Sigma Labs, Inc. is a provider of quality assurance software
under the PrintRite3D® brand and a developer of advanced,
in-process, non-destructive quality assurance software for
commercial firms worldwide seeking productive solutions for
advanced manufacturing. For more information please visit us at
www.sigmalabsinc.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended (which Sections were adopted as part of the Private
Securities Litigation Reform Act of 1995). Statements preceded by,
followed by or that otherwise include the words “believe,”
“anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,”
“prospects,” “outlook,” and similar words or expressions, or future
or conditional verbs such as “will,” “should,” “would,” “may,” and
“could” are generally forward-looking in nature and not historical
facts. These forward-looking statements involve known and unknown
risks, uncertainties and other factors which may cause the
Company's actual results, performance or achievements to be
materially different from any anticipated results, performance or
achievements. The Company disclaims any intention to, and
undertakes no obligation to, revise any forward-looking statements,
whether as a result of new information, a future event, or
otherwise. For additional risks and uncertainties that could impact
the Company’s forward-looking statements, please see the Company’s
Annual Report on Form 10-K (including but not limited to the
discussion under “Risk Factors” therein) filed with the SEC on
April 17, 2018 and which may be viewed at http://www.sec.gov.
Investor Relations Contact:Bret ShapiroManaging
DirectorCORE IR561-479-8566 brets@coreir.com
|
Sigma Labs, Inc. |
Condensed Balance
Sheets |
(Unaudited) |
|
|
|
|
|
|
|
|
December 31, 2018 |
|
December 31, 2017 |
|
|
|
|
|
|
|
ASSETS |
Current Assets: |
|
|
|
|
|
Cash |
$ |
1,279,782 |
|
|
$ |
1,515,674 |
|
|
|
Accounts
Receivable, net |
|
38,800 |
|
|
|
104,538 |
|
|
|
Note
Receivable, net |
|
121,913 |
|
|
|
788,500 |
|
|
|
Inventory |
|
240,086 |
|
|
|
192,705 |
|
|
|
Prepaid
Expenses |
|
67,255 |
|
|
|
55,278 |
|
|
Total Current
Assets |
|
1,747,836 |
|
|
|
2,656,695 |
|
|
|
|
|
|
|
|
Other Assets: |
|
|
|
|
|
Property
and Equipment, net |
|
277,944 |
|
|
|
411,643 |
|
|
|
Intangible Assets, net |
|
404,978 |
|
|
|
294,396 |
|
|
|
Investment in Joint Venture |
|
500 |
|
|
|
500 |
|
|
|
Prepaid
Stock Compensation |
|
- |
|
|
|
31,576 |
|
|
Total Other
Assets |
|
683,422 |
|
|
|
738,115 |
|
|
TOTAL ASSETS |
$ |
2,431,258 |
|
|
$ |
3,394,810 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS'
EQUITY |
Current
Liabilities: |
|
|
|
|
|
Accounts
Payable |
$ |
217,488 |
|
|
$ |
100,884 |
|
|
|
Dividends Payable - Preferred |
|
- |
|
|
|
- |
|
|
|
Notes
Payable |
|
50,000 |
|
|
|
100,000 |
|
|
|
Deferred
Revenue |
|
51,498 |
|
|
|
35,680 |
|
|
|
Accrued
Expenses |
|
376,833 |
|
|
|
146,330 |
|
|
Total Current
Liabilities |
|
695,819 |
|
|
|
382,894 |
|
|
TOTAL LIABILITIES |
|
695,819 |
|
|
|
382,894 |
|
|
|
|
|
|
|
|
Stockholders'
Equity |
|
|
|
|
|
Preferred Stock, $0.001 par; 10,000,000 shares authorized; |
|
|
|
|
0 shares
issued and outstanding |
|
- |
|
|
|
- |
|
|
|
Common Stock, $0.001 par; 22,500,000 shares authorized; |
|
|
|
|
8,776,629, and
4,978,929 issued and outstanding, respectively |
|
8,777 |
|
|
|
4,979 |
|
|
|
Additional Paid-In Capital |
|
21,501,407 |
|
|
|
17,192,394 |
|
|
|
Accumulated Deficit |
|
(19,774,745 |
) |
|
|
(14,185,457 |
) |
|
TOTAL STOCKHOLDERS' EQUITY |
|
1,735,439 |
|
|
|
3,011,916 |
|
|
TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY |
$ |
2,431,258 |
|
|
$ |
3,394,810 |
|
|
|
|
|
|
|
|
|
|
Sigma Labs, Inc. |
|
Condensed Statements of
Operations |
|
(Unaudited) |
|
|
|
|
|
|
|
Twelve Months Ended |
|
|
|
December 31,2018 |
|
December 31,2017 |
|
|
|
|
|
|
|
REVENUES |
$ |
388,574 |
|
|
$ |
641,049 |
|
|
|
|
|
|
|
|
COST OF REVENUES |
|
270,107 |
|
|
|
272,372 |
|
|
|
|
|
|
|
|
|
GROSS PROFIT
(Loss) |
|
118,467 |
|
|
|
368,677 |
|
|
|
|
|
|
|
|
EXPENSES |
|
|
|
|
|
Salaries
& Benefits |
|
2,056,584 |
|
|
|
1,509,672 |
|
|
|
Stock-Based Compensation |
|
1,145,530 |
|
|
|
719,796 |
|
|
|
Operating & R&D Costs |
|
493,410 |
|
|
|
302,043 |
|
|
|
Investor
& Public Relations |
|
633,035 |
|
|
|
554,990 |
|
|
|
Legal
& Professional Services Fees |
|
564,854 |
|
|
|
563,300 |
|
|
|
Office
Expense |
|
466,657 |
|
|
|
324,920 |
|
|
|
Depreciation & Amortization |
|
192,374 |
|
|
|
196,943 |
|
|
|
Other
Operating Expenses |
|
134,827 |
|
|
|
95,989 |
|
|
|
Total Expenses |
|
5,687,271 |
|
|
|
4,267,654 |
|
|
|
OPERATING INCOME (LOSS) |
|
(5,568,804 |
) |
|
|
(3,898,977 |
) |
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE) |
|
|
|
|
|
Interest
Income |
|
35,178 |
|
|
|
40,107 |
|
|
|
State
Incentives |
|
- |
|
|
|
154,568 |
|
|
|
Change
in fair value of derivative liabilities |
|
- |
|
|
|
(186,908 |
) |
|
|
Exchange
Rate Gain (Loss) |
|
162 |
|
|
|
- |
|
|
|
Interest
Expense |
|
(3,966 |
) |
|
|
(161,852 |
) |
|
|
Loss on
Disposal of Assets |
|
(36,733 |
) |
|
|
(13,161 |
) |
|
|
Debt
Discount Amortization |
|
- |
|
|
|
(358,280 |
) |
|
|
Total Other Income
(Loss) |
|
(5,359 |
) |
|
|
(525,526 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS BEFORE PROVISION FOR INCOME TAXES |
|
(5,574,163 |
) |
|
|
(4,424,503 |
) |
|
|
|
|
|
|
|
Provision for income Taxes |
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
Net
Loss |
$ |
(5,574,163 |
) |
|
$ |
(4,424,503 |
) |
|
|
|
|
|
|
|
Preferred
Dividends |
|
(15,125 |
) |
|
|
- |
|
|
|
|
|
|
|
|
Net
Loss applicable to Common Stockholders |
$ |
(5,589,288 |
) |
|
$ |
(4,424,503 |
) |
|
|
|
|
|
|
|
Net
Loss per Common Share - Basic and Diluted |
$ |
(0.81 |
) |
|
$ |
(1.00 |
) |
|
|
Weighted Average Number of
Shares |
|
|
|
|
Outstanding - Basic and
Diluted |
|
6,898,047 |
|
|
|
4,403,479 |
|
|
|
|
|
|
|
|
|
|
|
Sigma Labs, Inc. |
|
|
Condensed Statements of Cash
Flows |
|
|
For the Periods
Ended |
|
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
December 31, |
|
|
|
|
|
|
2018 |
|
|
|
2017 |
|
|
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
Net Loss |
$ |
(5,574,163 |
) |
|
$ |
(4,424,503 |
) |
|
|
|
|
|
|
|
|
|
|
|
Adjustments to reconcile Net Income (Loss) to Net Cash
used in operating activities: |
|
|
|
|
|
|
Noncash Expenses: |
|
|
|
|
|
|
|
Depreciation and Amortization |
|
192,374 |
|
|
|
196,943 |
|
|
|
|
|
Stock
Based Compensation |
|
1,145,530 |
|
|
|
719,796 |
|
|
|
|
|
Loss on
Writeoff of Assets |
|
36,733 |
|
|
|
13,161 |
|
|
|
|
|
Refund
on Write-off of Asset |
|
- |
|
|
|
15,700 |
|
|
|
|
|
Gain/Loss on Change in Derivative Balance |
|
- |
|
|
|
186,908 |
|
|
|
|
|
Original
Issue Discount Amortization |
|
- |
|
|
|
88,442 |
|
|
|
|
|
Debt
Discount Amortization |
|
- |
|
|
|
358,280 |
|
|
|
|
Change in assets and
liabilities: |
|
|
|
|
|
|
|
Accounts
Receivable, net |
|
65,738 |
|
|
|
183,698 |
|
|
|
|
|
Interest
Receivable |
|
34,390 |
|
|
|
- |
|
|
|
|
|
Inventory |
|
(24,844 |
) |
|
|
(5,464 |
) |
|
|
|
|
Prepaid
Assets |
|
(1,652 |
) |
|
|
(16,957 |
) |
|
|
|
|
Accounts
Payable |
|
116,604 |
|
|
|
(11,291 |
) |
|
|
|
|
Deferred
Revenue |
|
15,818 |
|
|
|
32,365 |
|
|
|
|
|
Accrued
Expenses |
|
230,501 |
|
|
|
24,529 |
|
|
|
|
|
NET CASH USED IN OPERATING ACTIVITIES |
$ |
(3,762,971 |
) |
|
$ |
(2,638,393 |
) |
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
Purchase
of Furniture and Equipment |
|
(79,116 |
) |
|
|
(69,463 |
) |
|
|
|
|
Purchase
of Intangible Assets |
|
(149,409 |
) |
|
|
(70,997 |
) |
|
|
|
|
Notes
Receivable |
|
632,197 |
|
|
|
(788,500 |
) |
|
|
|
|
NET CASH PROVIDED (USED) BY INVESTING
ACTIVITIES |
|
403,672 |
|
|
|
(928,960 |
) |
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
Proceeds from issuance
of Series B Convertible Preferred & Warrants |
|
1,000,000 |
|
|
|
- |
|
|
|
|
|
Proceeds from issuance
of Series C Convertible Preferred & Warrants |
|
350,000 |
|
|
|
- |
|
|
|
|
|
Proceeds from issuance
of Common Stock and Warrants |
|
2,040,100 |
|
|
|
5,823,300 |
|
|
|
|
|
Less Offering
Costs |
|
(443,700 |
) |
|
|
(750,664 |
) |
|
|
|
|
Payments on Notes
Payable |
|
- |
|
|
|
(500,000 |
) |
|
|
|
|
Proceeds from Exercise
of Warrants |
|
192,132 |
|
|
|
112,000 |
|
|
|
|
|
Dividends on
Preferred |
|
(15,125 |
) |
|
|
- |
|
|
|
|
|
NET CASH PROVIDED BY FINANCING ACTIVITIES |
|
3,123,407 |
|
|
|
4,684,636 |
|
153,013 |
|
|
|
|
|
|
|
|
|
NET CASH INCREASE (DECREASE) FOR PERIOD |
$ |
(235,892 |
) |
|
$ |
1,117,283 |
|
|
|
|
|
|
|
|
|
|
|
CASH AT BEGINNING OF PERIOD |
$ |
1,515,674 |
|
|
$ |
398,391 |
|
|
|
|
|
|
|
|
|
|
|
CASH AT END OF PERIOD |
$ |
1,279,782 |
|
|
$ |
1,515,674 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures: |
|
|
|
|
|
|
Noncash investing & financing activities
disclosure: |
|
|
|
|
|
|
|
Write-off of Derivative
Liability |
$ |
- |
|
|
$ |
(280,114 |
) |
|
|
|
|
Conversion of conv debt
for stock |
$ |
(50,000 |
) |
|
$ |
(408,566 |
) |
|
|
|
Other noncash operating activities
disclosure: |
|
|
|
|
|
|
|
Issuance of Common
Stock for Services |
$ |
256,264 |
|
|
$ |
75,578 |
|
|
|
|
Disclosure of cash paid
for: |
|
|
|
|
|
|
|
Interest |
$ |
12,205 |
|
|
$ |
89,348 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sigma Labs, Inc. |
|
Statement of Stockholders'
Equity |
|
For The Twelve Months Ended December 31, 2018
and the Year Ended December 31, 2017 |
|
|
Common StockShares |
|
Common StockAmount |
|
Additional Paidin Capital |
|
AccumulatedDeficit |
|
Totals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31,
2016 |
3,133,789 |
$ |
3,135 |
$ |
10,734,857 |
$ |
-9,760,954 |
$ |
977,038 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Services at a price of $1.72 |
20,000 |
|
20 |
|
34,384 |
|
|
|
34,404 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Services at a price of $3.25 |
5,232 |
|
5 |
|
16,999 |
|
|
|
17,004 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Services at a price of $2.27 |
7,489 |
|
7 |
|
16,993 |
|
|
|
17,000 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Services at a price of $2.07 |
8,213 |
|
8 |
|
16,992 |
|
|
|
17,000 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares sold in Dawson
& James Offering at a net price of $3.757 |
1,410,000 |
|
1,410 |
|
4,885,811 |
|
|
|
4,887,221 |
|
|
|
|
|
|
|
|
|
|
|
|
Warrants sold in Dawson
& James Offering at a price of $0.13 |
|
|
|
|
183,300 |
|
|
|
183,300 |
|
|
|
|
|
|
|
|
|
|
|
|
Warrents sold at a
price of $.01 |
|
|
|
|
2,115 |
|
|
|
2,115 |
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount on notes
payable |
- |
|
- |
|
0 |
|
- |
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares Issued from
exercise of Warrants |
141,000 |
|
141 |
|
-141 |
|
- |
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares forfeited |
-8,250 |
|
-8 |
|
-9,822 |
|
- |
|
-9,830 |
|
|
|
|
|
|
|
|
|
|
|
|
Fractional shares
issued at reverse stock split |
1,178 |
|
1 |
|
- |
|
- |
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares Issued for Note
Payables Conversions |
200,000 |
|
200 |
|
399,800 |
|
|
|
400,000 |
|
Shares Issued for
Accrued Interest on Noter Payable (L1) |
4,278 |
|
4 |
|
8,552 |
|
|
|
8,556 |
|
Shares Issued from
exercise of Warrants (L1) |
56,000 |
|
56 |
|
111,944 |
|
|
|
112,000 |
|
Writeoff of Derivative
Liability upon note conversions |
|
|
|
|
280,114 |
|
|
|
280,114 |
|
|
|
|
|
|
|
|
|
|
|
|
Stock options awarded
to employees |
|
|
|
|
510,496 |
|
|
|
510,496 |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the twelve
months ended December 31, 2017 |
|
|
|
|
|
|
-4,424,503 |
|
-4,424,503 |
|
Balance December 31,
2017 |
4,978,929 |
$ |
4,979 |
$ |
17,192,394 |
$ |
-14,185,457 |
$ |
3,011,916 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Services at a price of $1.72 |
23,256 |
|
23 |
|
39,977 |
|
- |
|
40,000 |
|
Shares issued for
Services at a price of $1.2236 |
176,744 |
|
177 |
|
216,087 |
|
- |
|
216,264 |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Preferred
Shares issued in PIPE |
- |
|
- |
|
877,499 |
|
|
|
877,499 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Conversion of Preferred |
1,000,000 |
|
1,000 |
|
-999 |
|
- |
|
1 |
|
Preferred Dividends
Paid upon Conversion |
|
|
|
|
|
|
-15,125 |
|
-15,125 |
|
Shares Issued for Note
Payables Conversions |
25,000 |
|
25 |
|
49,975 |
|
- |
|
50,000 |
|
Shares Issued for
Cashless Exchange of Warrants |
4,800 |
|
5 |
|
-5 |
|
- |
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares sold in DJames
Public Offering at a net price of $0.895 |
2,040,000 |
|
2,040 |
|
1,720,360 |
|
- |
|
1,722,400 |
|
Series C Convertible
Preferred Shares Issued |
|
|
|
|
346,500 |
|
|
|
346,500 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for
Conversion of Preferred |
350,000 |
|
350 |
|
-350 |
|
- |
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Shares Issued from
exercise of Warrants |
177,900 |
|
178 |
|
191,954 |
|
- |
|
192,132 |
|
|
|
|
|
|
|
|
|
|
|
|
Stock options awarded
to employees |
- |
|
- |
|
868,015 |
|
- |
|
868,015 |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the Twelve
months ended December 31, 2018 |
0 |
|
0 |
|
0 |
|
-5,574,163 |
|
-5,574,163 |
|
Balance December 31,
2018 |
8,776,629 |
$ |
8,777 |
$ |
21,501,407 |
$ |
-19,774,745 |
$ |
1,735,438 |
|
|
|
|
|
|
|
|
|
|
|
|
Sigma Labs (NASDAQ:SGLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sigma Labs (NASDAQ:SGLB)
Historical Stock Chart
From Apr 2023 to Apr 2024